Filing Flows › Balchem (BCPC) › Q3 2026 › vs Q2 2026
Balchem (BCPC) Q3 2026 vs Q2 2026 (quarter over quarter)
Balchem's revenue rose $6.7M (+2%) from $284M in Q2 2026 to $291M in Q3 2026. The biggest changes: Product Sales Revenue +$6.9M (+2%); Royalty Revenue −$233K (-37%). Gross margin 36.4% against 36.5% (-0.1 pts).
Balchem, Q3 2026: revenue $291M (+9% year over year), operating margin 21.5%, net earnings $46.7M, operating cash flow $69.8M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 36.4% | 36.5% | -0.1 pts |
| Operating margin | 21.5% | 20.9% | +0.6 pts |
| Net margin | 16.1% | 15.7% | +0.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product Sales Revenue | $290M | $283M | $6.9M | +2% |
| Royalty Revenue | $401K | $634K | −$233K | -37% |
| Revenue | $291M | $284M | $6.7M | +2% |
| Gross profit | $106M | $104M | $2.0M | +2% |
| Cost of revenue | $185M | $180M | $4.6M | +3% |
| Operating profit | $62.4M | $59.2M | $3.2M | +5% |
| Operating expenses | $43.3M | $44.5M | −$1.2M | -3% |
| Pre-tax earnings | $60.0M | $57.8M | $2.3M | +4% |
| Other expense, net | $2.4M | $1.4M | $953K | +66% |
| Research & development | $5.3M | $4.5M | $809K | +18% |
| Sales & marketing | $20.7M | $21.1M | −$447K | -2% |
| General & admin | $17.2M | $18.8M | −$1.5M | -8% |
| Net earnings | $46.7M | $44.6M | $2.1M | +5% |
| Income tax | $13.3M | $13.2M | $150K | +1% |
| Depreciation & amortization | $12.4M | $12.2M | $169K | +1% |
| Share-based compensation | $5.0M | $5.9M | −$882K | -15% |
| Working capital & other | $5.6M | −$16.0M | $21.7M | — |
| Operating cash flow | $69.8M | $46.7M | $23.1M | +49% |
Questions
How much did Balchem's revenue grow quarter over quarter in Q3 2026?
Balchem's revenue rose $6.7M (+2%) from $284M in Q2 2026 to $291M in Q3 2026.
What drove Balchem's revenue change in Q3 2026?
Product Sales Revenue +$6.9M (+2%); Royalty Revenue −$233K (-37%).